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ABSTRACT: The combination of early diagnosis and
complete surgical resection oﬀers the greatest prospect of
curative cancer treatment. An iodine-124/ﬂuorescein-based
dual-modality labeling reagent, 124I-Green, constitutes a
generic tool for one-step installation of a positron emission
tomography (PET) and a ﬂuorescent reporter to any cancer-
speciﬁc antibody. The resulting antibody conjugate would
allow both cancer PET imaging and intraoperative ﬂuores-
cence-guided surgery. 124I-Green was synthesized in excellent
radiochemical yields of 92 ± 5% (n = 4) determined by HPLC
with an improved one-pot three-component radioiodination
reaction. The A5B7 carcinoembryonic antigen (CEA)-speciﬁc
antibody was conjugated to 124I-Green. High tumor uptake of the dual-labeled A5B7 of 20.21 ± 2.70, 13.31 ± 0.73, and 10.64 ±
1.86%ID/g was observed in CEA-expressing SW1222 xenograft mouse model (n = 3) at 24, 48, and 72 h post intravenous
injection, respectively. The xenografts were clearly visualized by both PET/CT and ex vivo ﬂuorescence imaging. These
encouraging results warrant the further translational development of 124I-Green for cancer PET imaging and ﬂuorescence-guided
surgery.
■ INTRODUCTION
Cancer is a leading cause of death worldwide, accounting for
8.8 million deaths in 2015. About 14 million people are
diagnosed with cancer each year, and this ﬁgure is expected to
reach 27 million by 2030 according to the World Health
Organization.1 The combination of early diagnosis and
complete surgical removal represents the most eﬀective
therapeutic modality for malignant tumors.2
Positron emission tomography (PET) is a functional imaging
technique. By targeting cancer-associated biochemical varia-
tions at the molecular level, this imaging modality can detect
tumors at the earliest stages of malignancy. Currently, the 2-
deoxy-2-[18F]ﬂuoro-D-glucose (18F-FDG) based PET/CT scan
is routinely used for the diagnosis and prognostic assessment of
cancer patients.3 However, 18F-FDG is not cancer-speciﬁc.
Benign diseases such as inﬂammation or infection are also
associated with increased 18F-FDG uptake, resulting in false-
positive diagnosis.4 ImmunoPET employing positron emitter-
labeled tumor-speciﬁc monoclonal antibodies has shown great
promise to stage cancer patients and detect tiny tumor lesions
in several clinical trials thanks to their nanomolar binding
aﬃnity and speciﬁcity for tumor-associated biomarkers.5
Zirconium-89 (23% β+, T1/2 = 3.3 days) and iodine-124
(24% β+, T1/2 = 4.2 days) are the most commonly used
positron emitters in immunoPET due to their longer half-lives
that are compatible with the biological half-lives of the full-size
antibodies.6 In a feasibility study, 89Zr-trastuzumab targeting
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the human epidermal growth factor receptor 2 (HER2) allowed
PET imaging of most of the known tumors including brain
lesions in 14 patients with HER2-positive metastatic breast
cancer.7 Meanwhile, 124I-girentuximab targets the cell-surface
carbonic anhydrase IX that is homogeneously overexpressed in
more than 95% of clear cell renal cell carcinoma (ccRCC). It
showed superior sensitivity and speciﬁcity for detecting ccRCC
compared to the contrast-enhanced CT scanning in a
multicenter trial involving 195 patients.8
Once cancer patients are recommended for surgery, the
surgeon faces the challenge of pinpointing the exact sites of
tumor lesions and identifying the metastatic lymph nodes for
resection. To increase the accuracy of tumor delineation,
Larson et al. successfully applied 124I-girentuximab to the
preoperative mapping with PET and intraoperative localization
of ccRCC with a hand-held PET probe capable of measuring
both γ and β-emission.9 However, due to the limited spatial
resolution of the hand-held radiation detection device, it is
challenging to distinguish the surgical margins and to identify
the interface between the tumor and the surrounding healthy
tissues. In contrast, ﬂuorescence imaging oﬀers superior spatial
resolution. Ntziachristos et al. demonstrated that a folate
receptor-targeting ﬂuorescein molecular probe oﬀered speciﬁc
and sensitive real-time identiﬁcation of tumor deposits with
clear surgical margins during ﬂuorescence-guided surgery in
ovarian cancer patients.10
To harness the synergistic property of PET and ﬂuorescence
imaging for cancer diagnosis and precise tumor resection,
considerable eﬀort has been made to develop dual PET and
ﬂuorescence imaging reagents.11−13 However, none of these has
been approved by the Food and Drug Administration (FDA).12
One limiting factor is the lack of a generic method to prepare
these reagents for screening.13 We envisage that a dual PET and
ﬂuorescent labeling reagent would act as a generic tool to install
both a PET and a ﬂuorescent reporter to any cancer targeting
antibody. Thus, it would standardize the preparation protocol,
accelerate the screening process, and minimize the translational
hurdle.
Recently, we reported a copper-mediated one-pot three-
component radioiodination method that allowed the reaction of
functionalized alkynes, azides, and radioactive iodine-125 (γ,
T1/2 = 60 days) to form trisubstituted iodotriazoles.
14,15 To
explore the potential of this chemistry in combinational cancer
diagnosis and surgery, we have synthesized a new dual modality
labeling reagent, 124I-Green. It is equipped with (i) a positron
emitter, iodine-124, for PET imaging of cancer, (ii) a clinically
approved green ﬂuorescent reporter, ﬂuorescein, for ﬂuores-
cence-guided surgery, and (iii) a succinimide moiety for
antibody coupling (Scheme 1). Here, we exemplify the utility
of this approach to allow the one-step installation of a dual PET
and ﬂuorescence reporter to a carcinoembryonic antigen
(CEA) speciﬁc murine antibody A5B7. The dual labeled
A5B7 oﬀered excellent tumor-to-background contrast in both
PET/CT and ex vivo ﬂuorescence imaging.
■ RESULTS
Synthetic Chemistry and Radiolabeling. Initially, 5(6)-
carboxyﬂuorescein was treated with N,N-diisopropylethylamine
in DMF to form the corresponding lactone and then reacted
the carboxylic group with propargylamine using propylphos-
phonic anhydride as the coupling reagent at 0 °C to form the
N-propargyl-5(6)-carboxyﬂuoresceinamide in 30% yield. The 4-
Scheme 1. Synthesis of the Dual PET and Fluorescent Labeling Reagent, 124I-Greena
a(i) propargylamine, propylphosphonic anhydride, DIPEA, DMF, 0 °C to rt, 18 h, 30%; (ii) (a) CuI, TEA, 4-azidomethyl-N-succinimidyl benzoate,
NIS, DMF, 18 h, 37% when I* = 127I, or (b) CuCl2, TEA/TEA·HCl, bathophenanthroline (10 mol %), 4-azidomethyl-N-succinimidyl benzoate,
[124I]NaI, DMF/CH3CN/H2O, 90 min when I* =
124I.
Table 1. Optimization of the Radioiodination of the Dual Labeling Reagent
entrya ligand (10 mol %) temperature (°C) time (min) RCY (%)b
1 N/A rt 90 4
2 N/A 60 90 40
3 1,10-phenanthroline rt 90 75 ± 10 (n = 3)
4 4,7-dichloro-1,10-phenanthroline rt 90 58
5 4,7-dimethoxy-1,10-phenanthroline rt 90 40
6 bathophenanthroline rt 90 91 ± 4 (n = 6)
7 bathophenanthroline (50 mol %) rt 90 73
8 bathophenanthroline rt 60 66
9c bathophenanthroline rt 90 25
10c,d bathophenanthroline rt 90 92 ± 5 (n = 4)
aSuspension of N-propargyl-5(6)-carboxyﬂuoresceinamides (1.0 μmol), CuCl2 (1.0 μmol) TEA (1.5 μmol) and ligand (mol %) was added to a
mixture of azidomethyl-N-succinimidyl benzoate (1.0 μmol) and [125I]NaI (6 μL). bRadiochemical yield was determined by HPLC. c[124I]NaI was
used for the reaction. dTEA·HCl was used to neutralize the NaOH in the aqueous [124I]NaI.
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azidomethyl-N-succinimidyl benzoate was also prepared
following a literature method in two steps with an overall of
yield 61%.14 Subsequently, the nonradioactive reference
compound of 124I-Green was synthesized from the reaction of
N-propargyl-5(6)-carboxyﬂuoresceinamide, 4-azidomethyl-N-
succinimidyl benzoate, and N-iodosuccinimide in the presence
of copper(I) iodide in DMF with a moderate yield of 37%
(Scheme 1.). Next, we systematically screened diﬀerent
conditions to optimize the radiochemical preparation of 124I-
Green. [125I]NaI was used as the surrogate of [124I]NaI for the
optimization of the radiolabeling. Under the previously
published conditions, low radiochemical yields (RCYs) of 4%
and 40% measured by HPLC were observed at room
temperature (rt) and 60 °C, respectively (Table 1, entries 1
and 2). Screening of 1,10-phenanthroline copper ligands
revealed bathophenanthroline to be optimal for the reaction
and provided the 125I-labeled target compound in excellent
RCYs of 91 ± 4% measured by HPLC (n = 6) (Table 1, entry
6). When these optimized conditions were applied to the 124I-
radiolabeling, excellent RCYs of 92 ± 5% (n = 4) measured by
HPLC were achieved in the presence of TEA·HCl (Table 1,
entry 10, and Supporting Information, Figure S1). The identity
of 124I-Green was proved by co-eluting with its nonradioactive
reference compound (Supporting Information, Figure S2).
When prepared under the optimized conditions starting with
around 36 MBq of [124I]NaI, 124I-Green was isolated in
radioactivity yields of 78 ± 6% (n = 3) with the radiochemical
purity ≥95% (Supporting Information, Figure S2) and the
molar activity around 3.5 GBq/μmol.
Dual Labeling Reagent Antibody A5B7 Conjugation
and Characterization. Next, we conjugated 124I-Green with a
murine CEA speciﬁc antibody A5B7. The A5B7 was incubated
with 124I-Green in 10 mM pH 9.0 carbonate buﬀer at rt for 45
min. Good labeling eﬃciency of 60 ± 5% (n = 3) was achieved
(Supporting Information, Table S1, entry 1) after size exclusion
column puriﬁcation. The recovery eﬃciency of 124I-Green
A5B7 conjugate from this size exclusion column was also
determined as 80 ± 4% (n = 3) by passing the puriﬁed 124I-
Green labeled A5B7 conjugate through a new size exclusion
column. To determine the optimal number of ﬂuorophores per
antibody, we co-incubated the A5B7 with a mixture of 124I-
Green and diﬀerent amount of the nonradioactive reference
compound in 2, 5, 10, and 20 equiv of the antibody in 10 mM
pH 9.0 carbonate buﬀer at rt for 45 min. The radiolabeling
eﬃciencies were approximately 45%, 34%, 27%, and 25% (n =
3), respectively. The average ﬂuorophore per antibody was then
determined as 1, 2, 3, or 6, respectively (corrected for the loss
of 124I-Green A5B7 conjugate on the size exclusion column)
(Supporting Information, Table S1 entries 2−5). Subsequently,
the ﬂuorescence intensity of the dual labeled A5B7 (50 μg)
with 1, 2, 3, or 6 ﬂuorophores per antibody was measured from
508 to 572 nm with an excitation wavelength at 460 nm. The
dual labeled A5B7 with two ﬂuorophores per antibody emitted
the strongest ﬂuorescence between 526 and 572 nm (Figure
Figure 1. Fluorescence intensity of the dual labeled A5B7 (50 μg) with 1, 2, 3, or 6 ﬂuorophores per antibody. Data are representative of three
independent replicates (A). ELISA analysis to determine the EC50 of the dual labeled A5B7 with two ﬂuorophores per antibody and the native A5B7
(mean ± SD, n = 3 independent replicates) (B).
Figure 2. Fluorescence images of SW1222 cells stained with the dual labeled A5B7 antibody and bisbenzimide H 33342, without (A) and with
blocking using the native A5B7 (B) in vitro. Fluorescence image of an SW1222 tumor xenograft section stained with the dual labeled A5B7 antibody
and the bisbenzimide H 33342 in vitro (C).
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1A) and was therefore selected for further evaluation. HPLC
analysis using a size exclusion column revealed comparable
retention times for the dual labeled A5B7 conjugate (8.61 min)
and native A5B7 (8.55 min). The absence of other peaks in the
HPLC chromatogram suggests that labeling and puriﬁcation
were achieved without causing antibody aggregation (Support-
ing Information, Figure S3). To assess whether the dual labeled
A5B7 preserved its binding aﬃnity, we carried out an enzyme-
linked immunosorbent assay (ELISA) to measure the half-
maximal eﬀective concentration (EC50) of the dual labeled and
the native A5B7 to the CEA. The absorbance of the dual
labeled A5B7 was very close to the native antibody at all nine
concentrations (Figure 1B), and its EC50 was determined as
21.12 ± 1.20 nM, which is similar to the native A5B7 (26.00 ±
1.13 nM) (n = 3).
In Vitro Biological Evaluation of the Dual Labeled
A5B7. The dual labeled A5B7 (7 μg/mL) was incubated with
the CEA-expressing human colorectal carcinoma SW1222 cells
at 37 °C for 1 h followed by bisbenzimide H 33342 for 5 min.
Bright-green ﬂuorescence from the stained SW1222 cells was
observed under a ﬂuorescence microscope (Figure 2A). When
co-incubated with the native antibody (39 μg/mL), cellular
uptake of the dual labeled A5B7 was largely blocked (Figure
2B). Next, the dual labeled A5B7 was incubated with the ﬁxed
SW1222 xenograft tissue sections at rt for 30 min followed by
bisbenzimide H 33342 for 5 min. Once again, strong and
sustained green ﬂuorescence was observed from the xenograft
tissue sections (Figure 2 C).
Biodistribution Study, PET/CT, and Ex Vivo Fluores-
cence Imaging. The biodistribution of 124I-Green dual labeled
A5B7 in SW1222 tumor xenograft-bearing CD1 nude mice (n =
3 per time point) was measured at 24, 48, and 72 h post-iv
injection (Figure 3). Higher radioactivity accumulation was
observed in the tumor, blood, and small intestine compared to
other organs. Tumor uptake was 20.21 ± 2.70, 13.31 ± 0.73,
and 10.64 ± 1.86 percentage injected dose per gram tissue (%
ID/g) at these three time points, respectively (Supporting
Information, Table S2). Uptake in the blood and small intestine
was 16.42 ± 1.01 and 10.50 ± 1.59%ID/g, respectively, at 24 h,
and rapidly decreased to 5.74 ± 2.27 and 2.02 ± 0.73%ID/g,
respectively, at 72 h post injection (Supporting Information,
Table S2).
Next, the 124I-Green dual labeled A5B7 in PBS was
intravenously injected into CD1 nude mice (n = 3) bearing
an established SW1222 tumor xenograft in the front-left ﬂank
area. Animals were imaged in three sequential 60 min PET/CT
scans, performed at 24, 48, and 72 h post injection. The
SW1222 tumor xenografts were clearly visualized in the 3D
PET/CT images at all three time points, although distribution
of the radioactivity signals within the tumors was heterogenious
(Figure 4A,B). Weaker radioactivity signals in the hearts were
observed at 24 and 48 h but were cleared in 72 h PET/CT
image (Figure 4B). Quantiﬁcation of radioactivity level in
selected organs including tumor, liver, and kidney was largely
consistent with the biodistribution data (Supporting Informa-
tion, Figure S4). As expected, accumulation of 124I in the
thyroid glands was also detected and the radioactivity levels
were quantiﬁed as 32.25 ± 3.24, 33.22 ± 1.09, and 36.92 ±
5.19%ID/mL at 24, 48, and 72 h post injection, respectively
(Supporting Information, Figure S4).
All three animals were sacriﬁced at the end of the last PET/
CT scan, and the SW1222 tumor xenografts were exposed.
When observed in a whole-body ﬂuorescence imaging system
with an excitation wavelength of 460 nm, the xenografts were
clearly visualized and distinguished from the surrounding tissue
(Figure 5A). As a result, complete resection of the tumor was
feasible (Figure 5B). The strength of ﬂuorescence emission
from the xenografts was compared with other major
thoracoabdominal organs. Apart from the stomach and the
large intestine, the tumor xenografts showed the strongest
ﬂuorescence (Figure 5C,D).
Ex Vivo Sequential Autoradiography and Fluores-
cence Imaging. Three tumor sections of a SW1222 xenograft
resected from a mouse post the PET/CT imaging were exposed
to a phosphor screen for 3 days. After scanning on a phosphor
imager, autoradiography demonstrated the uneven distribution
of the radioactivity in each tumor section (Figure 6A). The
same tumor sections where then analyzed for ﬂuorescence on
the same imager using the ﬂuorescein ﬁlter. The distribution
and the intensity of ﬂuorescence emission largely co-registered
with the radioactivity signals in the autoradiograph of the
corresponding tumor sections (Figure 6B).
■ DISCUSSION AND CONCLUSION
Biomedical imaging is an essential contributor to cancer patient
management that provides vital information required for cancer
staging, therapeutic planning, and the monitoring of disease
status.17 Multimodality imaging techniques can overcome the
limitations of each imaging modality and supply complemen-
tary information to improve cancer care. PET and ﬂuorescence
imaging are highly synergistic.12,13 The former can provide
quantitative measurement without limitation of penetration
depth, while the latter oﬀers superior spatial resolution. A
cancer-speciﬁc dual PET and ﬂuorescence imaging reagent
labeled with a longer half-life radioisotope such as 124I (T1/2 =
4.2 days) could enable the cancer surgical treatment to adopt a
highly integrated approach. PET/CT imaging of the malignant
lesions would enable more accurate preoperative surgical
planning. During surgery, the tumors and the metastatic
lymph nodes, especially the deep-lying deposits, could then be
rapidly localized with a hand-held radiation detector.
Subsequently, ﬂuorescence imaging would “light up” these
tumors for real-time assessment and more accurate resection.
To prepare our dual PET and ﬂuorescent labeling reagent,
we chose the FDA approved ﬂuorescein as the ﬂuorescent
reporter because it has successfully been used in ﬂuorescence-
guided surgery in clinical trials.10 The nonradioactive reference
Figure 3. Biodistribution of the 124I-Green dual labeled A5B7 in the
SW1222 tumor xenograft-bearing CD1 nude mice at 24, 48, and 72 h
post-iv injection (mean ± SD, n = 3 mice per time point).
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compound of 124I-Green was synthesized in a moderate yield of
37%. The 5(6)-carboxyﬂuorescein regioisomer mixture was
used for this proof-of-concept study due to its low cost relative
to the pure 5 or 6 regioisomers. The mixture has similar
chemical and photophysical properties as any of the single
regioisomer, and once coupled with an antibody the
Figure 4. Sequential 3D (A) and the corresponding axial (B) PET/CT images of a representative CD1 nude mouse bearing an SW1222 tumor
xenograft in the front-left ﬂank. Mice received 124I-Green dual labeled A5B7 and were imaged at 24, 48, and 72 h post-iv injection. Data are
representative of images obtained in three mice at these time points.
Figure 5. Ex vivo ﬂuorescence images of a representative CD1 nude mouse bearing an SW1222 tumor xenograft in the front-left ﬂank. Animals
received the 124I-Green dual labeled A5B7 and was imaged at 72 h post-iv injection before (A) and after complete tumor resection (B). The resected
tumor and major thoracoabdominal organs are shown under white-ﬁeld view (C) and ﬂuorescence-ﬁeld view (D). Data are representative of three
mice.
Figure 6. Ex vivo autoradiography of three SW1222 tumor xenograft tissue sections (A) and their corresponding ﬂuorescence images (B). Data are
representative of three tumor sections.
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pharmacokinetics of the conjugate will, in any case, be
dominated by the macromolecule. Next, we optimized the
radiosynthesis of 124I-Green. Iodine-125 was used as a surrogate
of iodine-124 (γmax 35 keV vs 1691 keV for
124I) for the
development work to reduce the cost of the screening and to
minimize ionizing radiation exposure. Poor RCYs of the dual
labeling reagent were initially obtained when applying the
previously published conditions for the formation of radio-
iodinated 1,2,3-triazoles.14,15 As a phenanthroline analogue has
been reported to accelerate the copper-mediated alkyne−azide
“click” reactions,18 we screened structurally related ligands and
found that addition of bathophenanthroline was beneﬁcial for
the radiochemical reaction. Using this ligand, 124I-Green was
obtained with excellent RCYs around 92% determined by
HPLC.
To explore the application of 124I-Green to cancer PET
imaging and ﬂuorescence-guided surgery, we selected a CEA-
speciﬁc murine monoclonal antibody A5B7, a CEA-expressing
SW1222 human colorectal cell line, and the corresponding
tumor xenograft to systematically evaluate this dual modality
imaging approach in vitro and in vivo. The speciﬁc binding of
the directly labeled 131I-A5B7 to the SW1222 cells and derived
xenografts is well documented in the literature.16,19 Further-
more, 131I-A5B7 has been employed in several clinical trials for
radioimmunotherapy of metastatic colorectal tumors and
advanced gastrointestinal carcinomas.20,21 Initially, to optimize
the number of ﬂuorophores coupled to the A5B7, we
conjugated 1, 2, 3, or 6 of the nonradioactive reference
compound per A5B7 molecule under mild basic conditions. As
too many ﬂuorophores were coupled to the antibody, this could
have a detrimental eﬀect on binding aﬃnity, promote antibody
aggregation, and reduce the strength of ﬂuorescence through
self-quenching. It became apparent that coupling of two
ﬂuorophores per A5B7 antibody emitted the strongest
ﬂuorescence. Moreover, this dual labeled A5B7 has similar
EC50 and HPLC retention time to the native antibody,
indicating that its binding aﬃnity was preserved and that no
antibody aggregation took place. When incubated with the
CEA-expressing SW1222 cells, the cells were stained with
bright-green ﬂuorescence. This was largely blocked by the
native A5B7 antibody, demonstrating the speciﬁc binding of the
dual labeled A5B7 to the CEA in live cells. Furthermore,
intense green ﬂuorescence was observed in an SW1222 tumor
xenograft tissue section stained with the dual labeled A5B7,
indicating that it could illuminate the SW1222 tumor xenograft
in the ex vivo ﬂuorescence imaging for accurate tumor
resection.
Encouraged by these in vitro results, we investigated the
biodistribution of the 124I-Green dual labeled A5B7 in the
SW1222 tumor xenograft mouse model at 24, 48, and 72 h
post-iv injection. The high tumor uptake and low uptake in
thoracoabdominal organs was similar to that previously
reported for the directly labeled 131I-A5B7.16,19 The initially
high blood pool and small intestine uptake observed at 24 and
48 h, clearing to background levels at 72 h, were in good
agreement with the biodistribution pattern of a full size
antibody. To demonstrate the translational potential of the 124I-
Green dual labeled A5B7 for the cancer PET imaging and
ﬂuorescence-guided surgery, we carried out three sequential
PET/CT scans of SW1222 tumor xenograft-bearing mice at 24,
48, and 72 h post-iv injection followed by ex vivo ﬂuorescence
imaging. The tumor xenografts were clearly visualized at all
three time points, reﬂecting the high aﬃnity and speciﬁcity of
the 124I-Green dual labeled A5B7 for CEA. Furthermore,
uneven distribution of the radioactivity was observed in the
tumor xenografts from the PET images, probably due to the
heterogeneity of these tumors. In addition, signiﬁcant thyroid
uptake was observed in the PET images, most likely because of
the catabolism of the 124I-Green dual labeled A5B7, generating
free iodine-124 which subsequently accumulated in the thyroid.
It was noted that the thyroid uptake increased over time, while
the tumor, liver, and kidney levels gradually decreased. It
expected that this thyroid uptake can be blocked by feeding the
animals with 0.1% potassium iodide solution.19 Some radio-
activity was also observed in the hearts in the 24 h PET images,
owing to blood pool activity, but this had largely cleared by the
48 and 72 h PET images. The largest ratio of uptake by tumor
compared to blood and other thoracoabdominal organs was
observed at 72 h post-iv injection in the biodistribution study.
Consequently, we decided to carried out the ex vivo
ﬂuorescence imaging at this time point in order to obtain the
optimal tumor-to-background contrast. Indeed, tumor xeno-
grafts were clearly visualized and exhibited a clear boundary
with the surrounding tissue, which facilitated complete
resection of the tumor. When compared with other major
thoracoabdominal organs, the tumor xenografts emitted the
strongest ﬂuorescence apart from the stomach and the large
intestine. Much of the strong ﬂuorescence from the stomach
and large intestine appeared to arise from food and fecal
residue. However, the 124I-Green dual labeled antibody may
also be partially eliminated through the gut, contributing to
some of this background ﬂuorescence. In the control
experiments by treating two healthy animals with either native
or dual labeled A5B7, the ex vivo ﬂuorescence images at 72 h
post-iv injection showed identical high ﬂuorescence from the
stomach food and large intestine feces (Supporting Informa-
tion, Figure S5). In addition, tumor uptake was nearly 11 and 6
times greater than stomach and large intestine, respectively, at
this time point in the biodistribution study. Thus, it indicates
the majority of ﬂuorescence was from the food and feces
residue. This strong autoﬂuorescence is not expected to be a
problem in the clinical setting as all patients would be fasting
and subject to preoperative bowel preparation to ensure that
the colon is empty. Future development of the dual labeling
reagent with a near-infrared ﬂuorophore such as the
indocyanine green would further minimize the background
ﬂuorescence. In addition, we also performed sequential
autoradiography and ﬂuorescence imaging with the same
tumor tissue sections prepared using the xenografts from
PET/CT and ex vivo ﬂuorescence imaging. The distribution
patterns of the radioactivity and ﬂuorescence in these tumor
sections were largely identical, which further conﬁrmed that the
observed radioactivity signals and green ﬂuorescence in the
tumors were from 124I-Green. Detection of deeper tumor
lesions during ﬂuorescence-guided surgery is challenging due to
the limited tissue penetration of ﬂuorescence;22 in this context,
an added advantage of our 124I-Green is that it would enable the
complementary use of an intraoperative radioactivity detector
to map the gross locations of the tumors, followed by real-time
ﬂuorescence imaging to deﬁne the surgical margins and guide
complete tumor resection.
We have developed a generic dual PET and ﬂuorescent
labeling reagent, 124I-Green. This approach enables a one-step
installation of an iodine-124/ﬂuorescein dual reporter to any
antibody. When coupled with the CEA speciﬁc antibody A5B7,
the aﬃnity of the dual labeled A5B7 was preserved. In vitro
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01746
J. Med. Chem. 2018, 61, 1636−1645
1641
ﬂuorescence imaging of CEA overexpressing SW1222 cells
indicated the speciﬁc binding of the dual labeled A5B7 to its
antigens. The SW1222 xenografts in nude mice were clearly
visualized by both PET/CT and ex vivo ﬂuorescence imaging
with excellent target-to-background contrast. These data
demonstrate the feasibility of 124I-Green as a generic tool to
label cancer-speciﬁc antibodies for malignant tumor PET
imaging and ﬂuorescence-guided surgery, prompting further
translational research toward clinical application.
■ EXPERIMENTAL SECTION
Synthetic Chemistry and Radiochemistry. General Informa-
tion. 1H and 13C NMR spectra were recorded at rt on a Bruker Avance
400 instrument operating at the frequency of 400 MHz for 1H and 100
MHz for 13C. Chemical shifts are reported in ppm relative to DMSO
(σ 2.48, m) or CH3CN (σ 1.94, s), and coupling constants (J) are
given in hertz. HPLC analysis was performed with an Agilent 1200
HPLC system equipped with a 1200 series diode array detector and a
1200 series ﬂuorescence detector (G1321A). The chemical purity of
the nonradioactive reference compound of 124I-Green was determined
using HPLC, and it is greater than 95% (Supporting Information,
Figure S2). Radio-HPLC analysis was performed with an Agilent 1200
HPLC system equipped with a series diode array detector and Raytest
GABI Star radioactivity detector. Reductant-free [125I]NaI was
purchased from PerkinElmer (product no. NEZ033L020MC) in 1 ×
10−5 M NaOH (pH 8−11) aqueous solution. Reductant-free [124I]NaI
was purchased from PerkinElmer (product no. NEZ309) in 0.02 M
NaOH (pH 14) aqueous solution. All reagents were purchased from
Sigma-Aldrich and were used without further puriﬁcation. The
radiochemical purity of the 124I-Green was determined by radioHPLC,
and it is greater than 95% (Supporting Information, Figure S2).
N-Propargyl-5(6)-carboxyﬂuoresceinamide [1]. A solution of
5(6)-carboxyﬂuorescein (500 mg, 1.33 mmol) in DMF (16 mL) was
cooled to 0 °C using an ice bath under an atmosphere of nitrogen.
N,N-diisopropylethyl amine (0.93 mL, 5.31 mmol) was added
dropwise, and the solution was stirred for 20 min. A 50% solution
of propylphosphonic anhydride in ethyl acetate (3.96 mL, 6.55 mmol)
was then added dropwise to the reaction and followed by addition of
propargylamine (127 μL, 1.99 mmol). The resulting solution was
stirred at 0 °C for 1 h and allowed to warm to room temperature
overnight. The reaction was quenched by addition of 1.0 M HCl (70
mL) and was extracted with ethyl acetate (3 × 30 mL). The organic
layer was washed with brine (70 mL) and then dried over MgSO4. The
solvent was removed under vacuum, and the crude material was
puriﬁed by ﬂash chromatography on silica gel using ethyl acetate (with
0.1% acetic acid) as eluent. The title compound was obtained as an
orange solid (165 mg, 30%). 1H NMR (400 MHz, DMSO-d6) δ 10.18
(s, 2H, OH), 9.32 (t, 3/5H, J = 6 Hz, NH), 9.16 (t, 2/5H, J = 6 Hz,
NH), 8.47 (s, 3/5H, ArH), 8.24 (d, 3/5H, J = 8 Hz, ArH), 8.16 (d, 2/
5H, J = 8 Hz, ArH), 8.07 (d, 2/5H, J = 8 Hz, ArH), 7.70 (s, 2/5H,
ArH), 7.38 (d, 3/5H, J = 8 Hz, ArH), 6.67 (m, 2H, ArH), 6.60−6.52
(m, 4H, ArH), 4.11 (dd, 6/5H, J = 6 Hz, 3 Hz, CH2), 3.99 (dd, 4/5H,
J = 6 Hz, 3 Hz, CH2), 3.18 (s, 3/5H, J = 3 Hz, CspH), 3.10 (s, 2/5H, J
= 3 Hz, CspH).
13C NMR (100 MHz, DMSO-d6) δ 168.1, 167.9, 164.3,
164.2, 159.6, 154.9, 152.7, 151.8, 139.8, 135.5, 135.4, 134.7, 129.5,
129.2, 128.4, 127.5, 126.5, 124.9, 124.3, 123.4, 122.4, 112.7, 112.6,
109.1, 108.9, 102.2, 80.9, 80.7, 73.1, 28.7, 28.6. HRMS (EI, m/z) [M +




Compound of 124I-Green]. To a solution of copper(I) iodide (18.4
mg, 96.76 μmol) and triethyl amine (6.5 μL, 48.38 μmol) in
anhydrous DMF (1.8 mL) was added the N-propargyl-5(6)-
carboxyﬂuoresceinamide (synthetic method in Supporting Informa-
tion) (20.0 mg, 48.38 μmol), 4-azidomethyl-N-succinimidyl benzoate
(13.2 mg, 48.38 μmol), and N-iodosuccinimide (12.0 mg, 53.33 μmol,
1.1 equiv). The resulting mixture was stirred under an atmosphere of
argon at rt overnight. The reaction was quenched with water (15 mL)
and extracted with ethyl acetate (3 × 10 mL). The organic layer was
dried over MgSO4, and the solvent was removed under vacuum. The
resulting crude material was puriﬁed by ﬂash column chromatography
on silica, eluting with DCM/methanol/AcOH (9/1/0.1) to yield the
title compound as an orange solid (14.5 mg, 37%). The HPLC
retention times were 26.7 and 27.6 min for the two regioisomers,
respectively, using a ZORBAX column (300SB-C18, 9.4 mm × 250
mm, 5 μm) with the following eluent: water (0.1% formic acid) as
solvent A and methanol (0.1% formic acid) as solvent B, going from
30% B to 60% of B in 25 min then to 90% B in 5 min and going back
to 30% B in 10 min and remaining at 30% B for an additional 10 min
with a ﬂow rate of 3.0 mL/min. 1H NMR (400 MHz, CH3CN-d3) δ
8.34 (s, 4/5H, ArH), 8.15 (d, 4/5H, J = 9 Hz, ArH), 8.09 (d, 6/5H, J =
8 Hz, ArH), 8.06 (d, 6/5H, J = 9 Hz, ArH), 7.68 (s, 1H, NH), 7.38 (d,
6/5H, J = 8 Hz, ArH), 7.26 (d, 2H, J = 9 Hz, ArH), 7.25 (d, 4/5H, J =
8 Hz, ArH), 6.69 (s, 2H, ArH), 6.63 (d, 2H, J = 9 Hz, ArH), 6.53 (d,
2H, J = 9 Hz, ArH), 5.74 (s, 6/5H, NCH2), 5.68 (s, 4/5H, NCH2),
4.66 (d, 6/5H, J = 6 Hz, CH2-NH), 4.50 (d, 4/5H, J = 6 Hz, CH2-
NH), 2.84 (s, 4H, CH2−CH2). 13C NMR (100 MHz, DMSO-d6) δ
179.4, 170.2, 168.1, 164.5, 164.3, 162.3, 161.4, 159.7, 151.8, 148.5,
148.4, 143.2, 143.0, 135.8, 134.8, 130.5, 129.2, 129.1, 128.7, 128.3,
126.5, 124.9, 124.0, 123.6, 112.7, 109.0, 102.2, 83.9, 52.8, 48.6, 35.8,
35.4, 30.7, 29.5, 25.5, 25.2. HRMS (EI, m/z) [M + H]: calcd 814.0641
for C36H25IN5O10
+, found 814.0662.
Radiolabeling. For 125I-Labeling. Copper(II) chloride (3.4 mg,
25.3 μmol), triethylamine (5.3 μL, 38.1 μmol, 1.5 equiv), and
bathophenanthroline (850 μg, 2.5 μmol, 10 mol %) were mixed in
anhydrous acetonitrile (500 μL). The resulting suspension (62.5 μL)
was added to N-propargyl-5(6)-carboxyﬂuoresceinamide (1.4 mg, 3.1
μmol) in anhydrous DMF (62.5 μL). The resulting red suspension (40
μL) was added to a mixture of 4-azidomethyl-N-succinimidyl benzoate
(226 μg, 1.0 μmol) in acetonitrile (20 μL) and [125I]NaI (∼10 MBq)
in 1 × 10−5 M NaOH solution (6.0 μL).
For 124I-Labeling. Copper(II) chloride (3.4 mg, 25.3 μmol),
triethylamine (4.4 μL, 31.5 μmol, 1.38 equiv), and bathophenanthro-
line (850 μg, 2.5 μmol, 10% mol) were mixed in anhydrous
acetonitrile (500 μL). The resulting suspension (62.5 μL) was
added to N-propargyl-5(6)-carboxyﬂuoresceinamide (1.4 mg, 3.1
μmol) in anhydrous DMF (62.5 μL). The resulting red suspension
(40 μL) was added to a mixture of 4-azidomethyl-N-succinimidyl
benzoate (226 μg, 1.0 μmol) and triethylamine hydrochloride (TEA·
HCl) (16.5 μg, 0.12 μmol) in acetonitrile (20 μL) and [124I]NaI (∼12
MBq) in 0.02 M NaOH solution (6.0 μL).
After incubation at rt for 90 min, the reaction mixture was quenched
with DMSO (100 μL) followed by water/MeOH (4:1, 1.0 mL). The
resulting solution was puriﬁed by HPLC using a ZORBAX column
(300SB-C18, 9.4 mm × 250 mm, 5 μm) with the following eluent:
water as solvent A and methanol (0.1% formic acid) as solvent B,
going from 30% B to 60% B in 25 min then to 90% B in 5 min and
going back to 30% B in 10 min and remaining at 30% B for an
additional 10 min with a ﬂow rate of 3.0 mL/min. The retention time
of the title compounds were 26.8 and 27.7 min for the two
regioisomers, respectively. 124I-Green was co-eluted with the non-
radioactive reference compound using the same HPLC method to
conﬁrm its identity. Formulation: 124I-Green HPLC eluent was diluted
to 15% MeOH in water and was loaded on a preconditioned Waters
C-18 light Sep-Pak cartridge [washing with MeOH (5 mL) and
followed by water (5 mL)]. After washing with water (5 mL), 124I-
Green was released using EtOH. The EtOH was removed with a
stream of nitrogen and 124I-Green was then redissolved in DMSO for
further use.
Antibody A5B7 Conjugation. The murine anti-CEA antibody
A5B716 (400 μL, 3.9 mg/mL) in pH 7.4 PBS was buﬀer exchanged
prior to conjugation on a PD-10 minitrap G-25 size exclusion column
(GE healthcare) eluting with 10 mM, pH 9.0 carbonate buﬀer. The
most concentrated fractions (200−800 μL) excluding the loading
volume were collected and the concentration of the resulting antibody
was determined as 2.2 mg/mL by Bradford protein assay with the
Pierce Coomassie (Bradford) Protein Assay Kit at absorbance 595 nm.
124I-Green (5.0 MBq) in DMSO (2.5 μL) and the nonradioactive
reference compound (0, 2, 5, 10, or 20 equiv. to the A5B7,
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respectively) in DMSO (2.5 μL) were added to the antibody A5B7
(100 μL, 2.2 mg/mL) in 10 mM, pH 9.0 carbonate buﬀer. The
resulting solution was incubated in the dark at rt for 45 min. The
reaction was diluted to a total volume of 500 μL using pH 7.4 PBS and
was puriﬁed on a PD-10 minitrap G-25 size exclusion column (GE
healthcare) eluting with pH 7.4 PBS. The fractions (200−700 μL)
containing the dual labeled antibody A5B7 were collected. The
puriﬁed A5B7 was submitted to HPLC analysis with a Phenomenex
size exclusion column (BioSep-SEC-S3000) eluting with PBS-EDTA/
water 1:1 using a ﬂow rate of 5.0 mL/min in 20 min with a UV
detection at 280 nm. Fluorescence emission spectra between 508 and
572 nm of each of the dual labeled A5B7 antibodies (50 μg) was
measured using the ﬂuorescence detector in an Agilent 1200 HPLC
system with an excitation wavelength of 460 nm. The antibody
recovery rate from the PD-10 column was determined by loading the
dual labeled A5B7 (50 KBq, 500 μL) on a PD-10 column and eluted
with pH 7.4 PBS. The radioactive fractions were collected and
measured with a Raytest GABI star radioactivity detector. The
antibody recovery rate was 80 ± 4% (n = 3). The average
ﬂuorophore(s) per antibody was then calculated based on the
following equation:
Average ﬂuorophore(s) per antibody = labeling eﬃciency ×
equivalents of added nonradioactive reference compound of dual
labeling reagent/recovery eﬃciency of dual labeled antibody from the
PD-10 column
ELISA Assay to Measure the EC50 of the Dual Labeled A5B7
with CEA. A 96-well plate was coated with carcinoembryonic antigen
(CEA) at 10 μg/mL in PBS (100 μL) at 4 °C for 24 h. The plate was
washed with PBS and blocked with 5% marvel/PBST (150 μL) at rt
for 1 h. Serial dilutions of the dual labeled or native A5B7 (100 μL,
0.03 nM, 0.14 nM, 0.70 nM, 3.0 nM, 19.2 nM, 96.0 nM, 480.0 nM, 2.4
μM, and 8.3 μM) were added to the plate and incubated at rt for 2 h.
The plate was washed with PBS Tween-20 and deionized water, after
which the sheep antimouse-horseradish peroxidase-IgG (100 μL) was
added and incubated at rt for another 1 h. The samples were then
washed with PBS Tween-20 and deionized water. O-Phenylenedi-
amine dihydrochloride solution (100 μL) was added to the samples,
and color was developed in 5−10 min before addition of HCl (100 μL,
4.0 M). The absorbance was then read at 490 nm. The experiments
were repeated three times. The data were analyzed using GraphPad
Prism 7 software.
Cell Line. The human CEA-producing colorectal adenocarcinoma
cell line SW1222 was obtained from the European Collection of Cell
Cultures.16 Cells were cultured in DMEM medium supplemented with
10% FBS, 200 U/L penicillin, 0.1 g/L streptomycin, and 2 mM L-
glutamine at 37 °C under humidiﬁed atmosphere containing 5% CO2.
Tumor Xenograft Model. The human colorectal adenocarcinoma
cell line SW1222 was used to develop a subcutaneous xenograft model
by injecting 5 × 106 cells in 100 μL of saline into the front left ﬂanks of
4 week old female CD1 nude mice. The CEA expression in the
SW1222 tumor xenografts was previously quantiﬁed as 22−70 μg/g
tumor.16 Tumor volume was estimated using the formula V = (L × W
× H)/2 and the xenograft was established within 2 weeks. All animal
experiments complied with the Animals (Scientiﬁc Procedures) Act
(UK 1986) and Home Oﬃce (UK) guidelines and were conducted
under a Home Oﬃce license (P9C94E8A4) with local ethical approval
by the KCL College Research Ethics Committee (CREC).
In Vitro SW1222 Cell Staining and Blocking Study. SW1222
cells (1 × 106) were plated on a 6-well plate and incubated in the cell
culture media for 18 h. The medium was then removed, and the
adherent cells were washed twice with PBS (2.0 mL). The dual labeled
A5B7 (7 μg/mL) in PBS (1.0 mL) was added, followed by addition of
either the native A5B7 solution (10 μL, 3.9 mg/mL) to three wells for
blocking study or PBS (10 μL) to the remaining three wells. The cells
were incubated for 1 h at 37 °C, 5% CO2. Bisbenzimide H 33342
(Hoechst 33342) (10 μL, 0.25 mM) was then added 5 min before the
end of the incubation period. Subsequently, the solution was removed
and the cells were washed twice with ice-cold PBS (2.0 mL) before
being viewed under a digital inverted ﬂuorescence microscope EVOS ﬂ
(40× objective, AMG, USA) and the default light cubes GFP and
DAPI were selected for ﬂuorescein and Hoechst, respectively.
Immunoﬂuorescence Imaging. Frozen SW1222 tumor xeno-
graft sections (10 μm) were ﬁxed in acetone for 10 min at rt, incubated
in 3% normal serum/PBS for 30 min, and then incubated with the dual
labeled A5B7 (5 μg/mL) for another 30 min. Hoechst 33342 (10 μL,
0.25 mM) was then added 5 min before the end of the incubation
period. After rinsing with PBS, sections were mounted in PBS and
viewed under a digital inverted ﬂuorescence microscope EVOS ﬂ (4×
objective, AMG, USA) and the default light cubes GFP and DAPI
were selected for ﬂuorescein and Hoechst, respectively.
Dual Labeled A5B7 Biodistribution Studies. CD1 nude mice
bearing established SW1222 tumor xenografts were intravenously
injected with approximately 0.8 MBq of the 124I-Green dual labeled
A5B7 (∼44 μg) in 100 μL of PBS. The mice (n = 3) were culled by
cervical dislocation at 24, 48, and 72 h post-iv injection, respectively.
The tumor xenograft, major thoracoabdominal organs, left femur, and
thigh muscle were harvested, weighed, and gamma-counted. The
radioactivity in each organ was expressed as % ID/g. The total injected
dose was deﬁned as the sum of the whole body counts excluding the
tail.
PET/CT and Ex Vivo Fluorescence Imaging. Preclinical PET/
CT images were acquired using a NanoScan PET/CT (Mediso,
Budapest, Hungary) scanner with mice under isoﬂurane (2% in
oxygen) anesthesia. The SW1222 tumor xenograft-bearing CD1 nude
mice (n = 3) each received approximately 0.8 MBq of the 124I-Green
dual labeled A5B7 (∼44 μg) in PBS (100 μL) via iv injection. PET
scanning was performed for 60 min at 24, 48, and 72 h postinjection
followed by a CT scan. All PET/CT data were reconstructed with the
Monte Carlo-based full-3D iterative algorithm Tera-Tomo (Mediso
Medical Imaging Systems, Budapest, Hungary). Raw PET data were
reconstructed into 60 min bins using reconstruction settings (four
iterations, six subsets, 0.4 × 0.4 × 0.4 mm3 voxel size) as well as
intercrystal scatter correction. All reconstructed data were analyzed
with VivoQuant software (v3.0, inviCRO, LLC, Boston, USA). All
three animals were culled by cervical dislocation at the end of the last
PET/CT scan. The skin surrounding the front left ﬂanks was removed
to expose the tumor xenografts. Fluorescence images were taken using
a FOBI(tm) BGRN ﬂuorescent imaging system (Neoscience, Suwon,
Republic of Korea) both before and after the tumor resection.
Subsequently, the tumor xenografts, major thoracoabdominal organs,
and thigh muscle were harvested for ﬂuorescence imaging with the
FOBI ﬂuorescence imaging system with an excitation wavelength of
460 nm. All ﬂuorescence images were taken using LUCAM capture
software.
Ex Vivo Autoradiography and Fluorescence Imaging. Three
cryosections (5 μm thick) were prepared from the SW1222 tumor
xenografts collected 1 week after the PET/CT and ex vivo
ﬂuorescence imaging. These were allowed to air-dry and then exposed
to a phosphor screen (Molecular Dynamics) for 3 days. The phosphor
screen was scanned in a Typhoon 8600 phosphor imager at a
resolution of 50 μm. The same three tumor sections from the
autoradiography were then used for ﬂuorescence imaging in the same
imager with the default emission ﬁlter setting for ﬂuorescein
(ﬂuorescein 526 SP) with green laser (532 nm) at high sensitivity
with a resolution of 50 μm. All images were analyzed using ImageJ
software (v1.50i, NIH, USA)
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